Temedica, a Munich, Germany-based health insights company, raised €25M in Series B funding.
The round, which brought total funding raised to date to €42m, was led by MIG Capital, as well as a Munich-based family office.
The company intends to use the funds to accelerate expansion of its ecosystem, which provides holistic insights into the care realities and patient journeys of millions of patients by combining health-related data, and its development efforts.
Led by CEO and Founder Gloria Seibert, Temedica is a health insights company whose mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into insights in compliance with the GDPR.
From more than 40 billion data points on over 50,000 diagnoses, Temedica derives health-related insights on issues such as disease progression, treatment effectiveness, patient journeys, and medication adherence. The ecosystem brings together data from a wide variety of sources, such as registry data, sales data of medically relevant products, insurance data, patient experience data, and – with explicit patient consent – patient-generated data from patient companion apps. The insights gained from the connected data offer tangible added value to all stakeholders in the healthcare system: patients, health care professionals, clinics, research institutions, pharmaceutical and biotechnology companies, and pharmacies.
FinSMEs
24/11/2022